Biomarker: | MYCN positive |
---|---|
Cancer: | Neuroblastoma |
Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) + temozolomide (DNA synthesis inhibitor) + sirolimus (mTOR inhibitor) |
Direction: | Sensitive |